MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-08-2026
Assertio Holdings Total Liabilities 2011-2026 | ASRT
Annual Total Liabilities Assertio Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 173 M | 164 M | 148 M | 188 M | 224 M | 248 M | 469 M | 713 M | 869 M | 975 M | 1.05 B | 347 M | 371 M | 57.7 M | 58.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.05 B | 57.7 M | 404 M |
Quarterly Total Liabilities Assertio Holdings
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 136 M | 214 M | 180 M | 178 M | 164 M | 145 M | 147 M | 147 M | 148 M | 187 M | 151 M | 164 M | 188 M | 188 M | 194 M | 227 M | 224 M | 202 M | 220 M | 220 M | 248 M | 248 M | 248 M | 248 M | 469 M | 469 M | 469 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 469 M | 136 M | 223 M |
Total Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Evoke Pharma
EVOK
|
10.5 M | - | - | $ 36.6 M |  USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
250 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
12.7 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
63.2 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.6 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
449 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
26.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
107 M | - | - | $ 142 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
52.3 M | $ 5.53 | 2.22 % | $ 82.1 M | USA |
 |
Cronos Group
CRON
|
54.2 M | $ 2.67 | 2.3 % | $ 1.02 B |  Canada |
 |
Harrow Health
HROW
|
347 M | $ 30.86 | 0.59 % | $ 1.13 B | USA |
 |
Athenex
ATNX
|
228 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
90.4 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
6.15 B | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
367 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
173 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
10.3 B | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.5 | 3.38 % | $ 2.01 B | Canada |
 |
Organogenesis Holdings
ORGO
|
165 M | $ 2.55 | 4.94 % | $ 323 M | USA |
 |
Pacira BioSciences
PCRX
|
775 M | $ 23.0 | 3.09 % | $ 1.06 B | USA |
 |
Canopy Growth Corporation
CGC
|
430 M | $ 1.03 | 4.06 % | $ 111 M | Canada |
 |
Solid Biosciences
SLDB
|
52.5 M | $ 6.47 | 6.41 % | $ 566 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
9.28 M | $ 1.07 | 5.94 % | $ 1.33 M | USA |
 |
Aurora Cannabis
ACB
|
244 M | $ 3.47 | 5.15 % | $ 190 M | Canada |
 |
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
735 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
102 M | $ 1.07 | 2.88 % | $ 102 M | Canada |
 |
Tilray
TLRY
|
977 M | $ 5.41 | 3.84 % | $ 3.34 B | Canada |
 |
Evolus
EOLS
|
249 M | $ 6.59 | 2.49 % | $ 425 M | USA |
 |
Sundial Growers
SNDL
|
235 M | $ 1.44 | 4.35 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
1.17 B | $ 8.15 | 1.12 % | $ 417 M | USA |
 |
Veru
VERU
|
11.5 M | $ 2.17 | 2.84 % | $ 31.8 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
23.7 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
3.19 M | $ 0.75 | -0.27 % | $ 3.02 M | USA |
 |
ProPhase Labs
PRPH
|
24 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
434 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
478 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
7.49 M | $ 7.17 | 1.99 % | $ 283 M | USA |
 |
Recro Pharma
REPH
|
94.8 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
194 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
9.65 M | $ 0.67 | 1.67 % | $ 33.5 M | USA |
 |
PLx Pharma
PLXP
|
25 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
22.5 B | $ 16.59 | 2.6 % | $ 19.3 B | USA |
 |
Zomedica Corp.
ZOM
|
11.6 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.29 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
20.2 M | $ 0.82 | 2.71 % | $ 29.5 M | USA |
 |
Tricida
TCDA
|
168 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
8.26 M | $ 0.71 | -0.99 % | $ 3.05 M |  China |
 |
TherapeuticsMD
TXMD
|
10.8 M | $ 2.08 | 1.96 % | $ 24.1 M | USA |